Literature DB >> 18839078

Succinylcholine: a drug to avoid in bariatric surgery.

Talar Tejirian1, Catherine E Lewis, James Conner, Candice Jensen, Erik Dutson, Amir Mehran.   

Abstract

Succinylcholine is a paralytic agent regularly utilized in anesthesia. There are numerous adverse effects of succinylcholine ranging from mild to fatal; one such effect is succinylcholine myalgia. We report the case of a 34-year-old woman who received succinylcholine while undergoing laparoscopic Roux-en-Y gastric bypass and later developed succinylcholine myalgia leading to a prolonged hospital stay and subsequent pneumonia. In the presence of suitable alternative paralytic agents, succinylcholine should be avoided in patients undergoing bariatric surgery. The use of a designated anesthesia team familiar with bariatric operations can help maximize peri-operative management and minimize complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839078     DOI: 10.1007/s11695-008-9720-7

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  18 in total

Review 1.  Concepts in the prevention and management of malignant hyperthermia.

Authors:  Chad P Collins; O Ross Beirne
Journal:  J Oral Maxillofac Surg       Date:  2003-11       Impact factor: 1.895

Review 2.  Which muscle relaxants should be used in day surgery and when.

Authors:  Gabriella Bettelli
Journal:  Curr Opin Anaesthesiol       Date:  2006-12       Impact factor: 2.706

3.  How to inform a morbidly obese patient on the specific risk to develop postoperative pulmonary complications using evidence-based methodology.

Authors:  S Flier; J T A Knape
Journal:  Eur J Anaesthesiol       Date:  2006-02       Impact factor: 4.330

4.  Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity.

Authors:  P R Schauer; S Ikramuddin; W Gourash; R Ramanathan; J Luketich
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

5.  Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials.

Authors:  Jan-Uwe Schreiber; Christopher Lysakowski; Thomas Fuchs-Buder; Martin R Tramèr
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

6.  Gastroesophageal reflux disease in morbid obesity: the effect of Roux-en-Y gastric bypass.

Authors:  Mariel A Mejía-Rivas; Alejandro Herrera-López; Jorge Hernández-Calleros; Miguel F Herrera; Miguel A Valdovinos
Journal:  Obes Surg       Date:  2008-05-30       Impact factor: 4.129

Review 7.  The association between obesity and GERD: a review of the epidemiological evidence.

Authors:  Hashem El-Serag
Journal:  Dig Dis Sci       Date:  2008-07-24       Impact factor: 3.199

8.  Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.

Authors:  Friedrich K Pühringer; Christopher Rex; Andreas W Sielenkämper; Casper Claudius; Per Bo Larsen; Martine E Prins; Matthias Eikermann; Karin S Khuenl-Brady
Journal:  Anesthesiology       Date:  2008-08       Impact factor: 7.892

9.  Rhabdomyolysis after laparoscopic bariatric surgery.

Authors:  Philippe Mognol; Stéphane Vignes; Denis Chosidow; Jean-Pierre Marmuse
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

Review 10.  Surgery for obesity: a review of the current state of the art and future directions.

Authors:  Stephen S McNatt; James J Longhi; Charles D Goldman; David W McFadden
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

View more
  2 in total

1.  Succinylcholine in morbidly obese patients: another interesting advantage.

Authors:  Michele Carron; Ulderico Freo; Carlo Ori
Journal:  Obes Surg       Date:  2011-12       Impact factor: 4.129

2.  Succinylcholine: the dilemma with the evidence: comment on: Tejirian T, Lewis CE, Conner J et al. Succinylcholine: a drug to avoid in bariatric surgery. Obes Surg 2009; 19: 534-6.

Authors:  Jan-Uwe Schreiber; Thomas Fuchs-Buder
Journal:  Obes Surg       Date:  2009-10-14       Impact factor: 4.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.